A nomogram integrating the TyG index, FAI, and key clinical variables demonstrated excellent discriminative ability for predicting CHD risk in MAFLD patients with an AUC of 0.952.
Observational (n=435)
No
Do the TyG index and FAI predict the risk of coronary heart disease and functional ischemia in patients with MAFLD?
The combination of TyG index and pericoronary FAI provides high diagnostic accuracy for identifying coronary heart disease and functional ischemia in patients with MAFLD.
Effect estimate: AUC 0.952 (95% CI 0.935-0.970)
p-value: p=<0.001
Background This study evaluated coronary inflammation and insulin resistance (IR) using pericoronary fat attenuation index (FAI) and triglyceride-glucose (TyG) index, and assessed their associations with coronary heart disease (CHD) and functional ischemia in patients with metabolic dysfunction-associated fatty liver disease (MAFLD). Methods A total of 435 patients (174 MAFLD, 261 MAFLD+CHD) were included. The MAFLD+CHD group was stratified by CT-derived fractional flow reserve (CT-FFR) into 0.80 and ≤0.80 subgroups. FAI and CT-FFR were automatically calculated using AI-based software; Independent risk factors were identified using multivariable logistic regression analysis, based on which a nomogram was constructed. The predictive performance of the nomogram was evaluated using ROC curves, calibration curves, and decision curve analysis (DCA), with internal validation performed via the Bootstrap method. The predictive accuracy of the nomogram was also compared with that of FAI and the TyG index. Restricted cubic spline (RCS) models were employed to explore the potential nonlinear relationship between the TyG index and FAI, as well as the dose–response associations of these indices with disease risk. Results Multivariate logistic regression showed that TyG index and FAI were independent risk factors for CHD and coronary functional ischemia (P0.05), with CHD prevalence, functional ischemia, and TyG levels increasing alongside FAI. In MAFLD patients, the nomogram demonstrated excellent discrimination (ROC-AUC 0.952, 95% CI 0.935–0.970), and DCA, clinical net reduction, and clinical impact analyses confirmed its substantial clinical value in identifying high-risk CHD patients. For MAFLD patients with CHD, the nomogram also effectively predicted coronary functional ischemia (AUC 0.904, 95% CI 0.869–0.939). While FAI and TyG, alone or combined, had predictive value, the nomogram outperformed all single and combined indicators (AUCs 0.952 and 0.904; P0.001). RCS analysis revealed a linear positive correlation be-tween TyG and FAI, both positively associated with CHD and functional ischemia risk. Conclusion In patients with MAFLD and those with concomitant CHD, FAI was significantly positively correlated with the TyG index, and both were associated with the occurrence of CHD and coronary functional ischemia, suggesting that systemic metabolic dysfunction may promote disease progression through local coronary inflammation. Furthermore, a nomogram integrating the TyG index, FAI, and key clinical variables demonstrated excellent discriminative ability in internal validation, providing incremental diagnostic value for early CHD risk stratification in MAFLD patients.
Bai et al. (Thu,) conducted a observational in Metabolic dysfunction-associated fatty liver disease (MAFLD) with suspected coronary heart disease (CHD) (n=435). Nomogram integrating TyG index and FAI vs. Single indicators (TyG index or FAI alone) was evaluated on Prediction of CHD risk in MAFLD patients (AUC 0.952, 95% CI 0.935-0.970, p=<0.001). A nomogram integrating the TyG index, FAI, and key clinical variables demonstrated excellent discriminative ability for predicting CHD risk in MAFLD patients with an AUC of 0.952.